Trinity Biotech to submit IND for Uni-Gold HIV test within next three months.
This article was originally published in The Gray Sheet
Executive Summary
TRINITY BIOTECH UNI-GOLD HIV TEST INVESTIGATIONAL NEW DRUG SUBMISSION is expected within the next three months, the Dublin, Ireland-based company says. Clinical trials for the product will be conducted under FDA's new drug/biologic investigation procedures, and the company will attempt to bring the one-step HIV assay to market via a product license application (PLA) that will be reviewed by FDA's Center for Biologics Evaluation and Research. FDA is requiring Trinity to submit a PLA rather than a premarket approval application since the assay potentially could be used to screen blood, the firm explains.
You may also be interested in...
Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
World-First Nod For Yuhan's Lung Cancer Drug, In Korea
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes Gains US FDA Clearance For Velys Robot For Total Knee Surgery
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: